News|Articles|June 5, 2014

Bayer Extends CEO Contract

Bayer extends its CEO contract with Marijn Dekkers until 2016.

Bayer will extend Marijn Dekkers, PhD, contract as CEO for an additional two years, until the end of 2016.Werner Baumann, currently CFO, will become chief strategy and portfolio officer effective Oct. 1, 2014. Also effective Oct. 1, 2014, Johannes Dietsch, currently senior Bayer representative and CFO for Greater China based in Shanghai, will assume the position of CFO.

Source: Bayer

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Bayer Extends CEO Contract

Related Content

CPHI Milan Puts Sustainability to Work, Part 2

PharmTech Weekly Roundup—August 14, 2026

What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?

Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.

Trending on Pharmaceutical Technology

What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?

Danish Biotechs Attracting Investor Attention